7 Needs context
CT coronary angiography causes blooming artifact around preexisting coronary stents, preventing clear visualization inside the stent.
"And if you've had a stent already, you get what we call a blooming around that stent. So you can't read inside that." (said at 0:06:35)
Coronary CT angiography (CCTA) does indeed produce blooming artifacts around metallic stent struts due to beam hardening and partial volume effects. This artifact causes the metallic struts to appear thicker and artificially narrows the visible internal lumen (reducing visualized lumen diameter by approximately 30% compared to invasive angiography), creating substantial diagnostic challenges for detecting in-stent restenosis. However, stating that clinicians 'can't read inside' a stented vessel is an overstatement: while smaller stents (<3.0 mm) and certain alloys are frequently non-evaluable or obscured, larger stents (≥3.0 mm) and scans performed with newer technologies (such as high-definition CT, dual-source CT, and photon-counting detector CT) often permit diagnostic assessment of in-stent patency, exhibiting high negative predictive values.
Research indicates that approximately three-quarters of physicians cannot adequately assess prediabetes or metabolic disease.
"I mean, the research has shown that unfortunately three-quarters of docs can't really assess pre-diabetes, metabolic disease that well, but it's not because they can't. It's because they're too busy." (said at 0:10:12)
The statement reflects published survey findings evaluating primary care physicians' knowledge of prediabetes screening and diagnostic criteria, though framing it as 'three-quarters cannot adequately assess' requires context. In a cross-sectional survey of primary care providers by Tseng et al. (2017), only 17% correctly identified the complete laboratory diagnostic criteria (both fasting plasma glucose and HbA1c thresholds) for prediabetes, and only 6% identified all screening risk factors. A subsequent national survey (Tseng et al., 2019) similarly documented substantial knowledge deficits regarding diagnostic criteria and preventive management guidelines, while noting system-level barriers and time constraints. Because these findings stem from cross-sectional surveys testing guideline recall rather than direct audits of clinical competence, the evidence is rated low certainty.
Clinical guideline committees state that if a patient has a coronary artery calcium score of zero, they do not need a statin.
"And the standards committees, to their credit, have said, look, if you have a zero calcium score, in other words, if you have plaque imaging and it shows no plaque, you don't need a statin." (said at 0:41:30)
The claim is partially accurate but requires qualification. The 2018 ACC/AHA Multi-Society Cholesterol Management Guideline endorses coronary artery calcium (CAC) testing in primary prevention for adults at borderline or intermediate risk to inform shared decision-making, and notes that if CAC is zero, statin therapy may be withheld or delayed (re-evaluating in 5 to 10 years). However, this recommendation applies specifically to primary prevention in intermediate/borderline-risk individuals, and the guidelines explicitly outline important exceptions where statins are still recommended despite CAC = 0 (e.g., severe hypercholesterolemia with LDL-C ≥ 190 mg/dL, diabetes mellitus, active cigarette smoking, or family history of premature ASCVD). Therefore, CAC = 0 does not unconditionally mean a patient does not need a statin.
The American Association of Clinical Endocrinologists advises against relying solely on HbA1c for the diagnosis of diabetes because hemoglobin variants, liver disease, kidney disease, and pregnancy can alter HbA1c levels.
"I'm going to tell you the American Association of Clinical Endocrinologists has said in their own standards, don't rely on A1C for diagnosis of diabetes. There are things like hemoglobin differences like Jesus has that can really impact this test. At the end of the day, it's a hemoglobin test. Liver disease, kidney disease, pregnancy, genetics from where you're from in the world, all these things can change A1C." (said at 0:52:03)
The claim provides helpful clinical context regarding the limitations of HbA1c, but overstates the American Association of Clinical Endocrinologists (AACE) stance as a blanket rejection of HbA1c for diabetes diagnosis. Published AACE guidelines explicitly include and recommend HbA1c ≥6.5% as an established diagnostic criterion alongside fasting plasma glucose and oral glucose tolerance testing. However, AACE consensus statements and guidelines advise caution and recommend relying on glucose-based testing rather than HbA1c when confounding conditions that alter erythrocyte turnover or hemoglobin glycation are present—such as hemoglobinopathies, pregnancy, hemolytic anemia, and advanced renal or liver disease.
- context: Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabete… (Postgraduate medicine 2011) · cited 14x in the literature
"Within the past 2 years, the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) have revised their guidelines for the diagnosis and treatment of type 2 diabetes mellitus (T2DM). Both organizations recommend a diagnostic glycated hemoglobin (HbA1c) of >6.5% (based on a new appreciation of the relationship between glycemia and complications) and fasting plasma glucose levels or an oral glucose tolerance test." (abstract, results, passage verified)
pubmedfull study (doi)
Studies by Paul Ridker and others have shown that low doses of statins taken intermittently (such as 5 mg every other day or twice a week) significantly reduce vascular inflammation.
"I know a lot of people and have discussed with people using even 5 every other day, even twice a week. And again, Paul Ridker, Gavin Blake, some other folks have demonstrated that you get an impact on vascular inflammation with these lower doses and taking them less often." (said at 0:53:50)
Randomized trials demonstrate that intermittent or alternate-day statin administration (such as rosuvastatin or atorvastatin administered every other day) significantly reduces high-sensitivity C-reactive protein (hs-CRP), a recognized biomarker of vascular and systemic inflammation. However, attributing intermittent dosing protocols specifically to Paul Ridker and Gavin Blake is slightly conflated: Ridker and Blake conducted foundational landmark research demonstrating that statin therapy directly reduces vascular inflammation and hs-CRP independently of LDL lowering, but their major clinical trials evaluated daily dosing regimens.
A high coronary calcium score reflects stable calcified plaque but does not indicate whether soft plaque is present.
"You understand what a high calcium means. You know, for example, as we've discussed already today, a high calcium score doesn't mean that you've got a ton of soft plaque. One of the things that I would advise my patients to do, one of the things I would do if I had a high calcium score, the next thing is we look and say, "Well, okay, that means we've got plaque, but it means we've got stable plaque. It does not mean that we've got soft plaque."" (said at 1:17:13)
The host's claim requires important context. Non-contrast coronary artery calcium (CAC) scoring specifically measures calcified atherosclerotic plaque, which represents dense, calcified regions. CAC imaging cannot directly visualize or quantify non-calcified ("soft") plaque; detailed characterization of soft plaque requires contrast-enhanced coronary computed tomography angiography (CCTA). However, while CAC scoring does not directly measure non-calcified plaque, higher CAC scores generally correlate with an increased overall burden of non-calcified plaque across patient strata. For example, median non-calcified plaque volume increases progressively from ~18 mm³ in patients with CAC of 0 to over 100–150 mm³ in those with CAC of 100–299. Therefore, while a high CAC score specifically quantifies calcified plaque, it does not mean soft plaque is absent, as calcified and non-calcified plaque burdens frequently coexist.
- context: CCTA-Derived coronary plaque burden offers enhanced prognostic value over CAC scoring in s… (European heart journal. Cardiovascular Imaging 2025) · cited 21x in the literature
"AI-driven assessment of coronary plaque burden enhances prognostic accuracy for future adverse cardiovascular events, highlighting the critical role of comprehensive plaque characterization in refining risk stratification strategies." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: Using AI-Quantitative CT to evaluate the relationship between coronary artery calcium and … (The international journal of cardiovascular imaging 2026)
"Reliance on either CAC or SIS alone may result in risk misclassification, especially for patients with CAC = 0, the majority of whom had non-calcified plaque by AI-QCT." (abstract, conclusion)
pubmedfull study (doi) - context: Symptom status and non-calcified plaque burden across CAC strata: insights from AI-based C… (The international journal of cardiovascular imaging 2026)
"Median NCP volumes were similar in both groups for CAC 0 (17.7 vs. 18.6 mm³, p = 0.96) and CAC 1-99 (50.8 vs. 56.3 mm³, p = 0.37). A significant difference emerged in the CAC 100-299 category: symptomatic patients had higher NCP (152.3 vs. 112.3 mm³, p = 0.035)." (abstract, results)
pubmedfull study (doi)
Coronary stents do not prevent heart attacks.
"You mentioned, I think you mentioned stents or bypass or something, and yeah, a stent, as we've seen in multiple places, stents don't really prevent heart attacks. What does prevent it is lifestyle, appropriate use of lifestyle." (said at 1:17:50)
In patients with stable coronary artery disease, large randomized controlled trials (including the COURAGE and ISCHEMIA trials) have demonstrated that coronary stenting (percutaneous coronary intervention, or PCI) combined with optimal medical therapy does not reduce the rate of myocardial infarction or all-cause mortality compared with medical therapy alone. However, the blanket claim requires context: in the setting of acute coronary syndromes (such as ST-elevation myocardial infarction, or STEMI), emergent stenting is an established, life-saving standard of care that limits infarct size and prevents recurrent ischemic events.
- supports: Optimal medical therapy with or without PCI for stable coronary disease. (The New England journal of medicine 2007) · cited 4721x in the literature
"There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, and stroke (20.0% vs. 19.5%; hazard ratio, 1.05; 95% CI, 0.87 to 1.27; P=0.62)... or myocardial infarction (13.2% vs. 12.3%; hazard ratio, 1.13; 95% CI, 0.89 to 1.43; P=0.33). As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy." (abstract, results and conclusions, passage verified)
pubmedfull study (doi) - supports: Initial Invasive or Conservative Strategy for Stable Coronary Disease. (The New England journal of medicine 2020) · cited 2439x in the literature
"Among patients with stable coronary disease and moderate or severe ischemia, we did not find evidence that an initial invasive strategy, as compared with an initial conservative strategy, reduced the risk of ischemic cardiovascular events or death from any cause over a median of 3.2 years." (abstract, conclusions, passage verified)
pubmedfull study (doi) - context: COURAGE, ORBITA, and ISCHEMIA: Percutaneous Coronary Intervention for Stable Coronary Arte… (Interventional cardiology clinics 2020) · cited 8x in the literature
"Anginal relief remains the primary indication for PCI in stable CAD... PCI in stable CAD has not been shown to improve mortality or overall myocardial infarction rates, even in the presence of significant ischemia. Rather, risk reduction medical therapy remains the main intervention for improving outcomes." (abstract, conclusions)
pubmedfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.